Awards & Advancement

Bristol-Myers Squibb appoints three new independent directors

Tuesday, February 21, 2017

Bristol-Myers Squibb has appointed Robert J. Bertolini, Matthew W. Emmens and Theodore R. Samuels to its board of directors, effective immediately. In connection with these appointments, the board will temporarily expand to 14 directors until the 2017 Annual Meeting, to be held on May 2, 2017. Only 11 directors will stand for election at the meeting. Bristol-Myers Squibb also announced that it has entered into an accelerated share repurchase (ASR) program to repurchase, in aggregate, $2 billion of Bristol-Myers Squibb’s common stock.

[Read More]

Certara Vice President Piet van der Graaf appointed F1000Prime faculty member

Thursday, February 16, 2017

Certara, a provider of decision support technology and consulting services for optimizing drug development and improving health outcomes, has announced that Professor Piet van der Graaf, PharmD, Ph.D., its vice president of quantitative systems pharmacology, has been appointed an F1000Prime faculty member. In this new role, Professor van der Graaf will contribute article reviews and recommendations to the Systems & Network Biology Section of the Bioinformatics, Biomedical Informatics & Computational Biology Faculty. He will be responsible for summarizing each article, explaining its value, and adding a rating score.

[Read More]

ERT named finalist for PACT Technology Company of the Year award

Thursday, February 16, 2017

ERT, a global data and technology company that minimizes risk and uncertainty in clinical trials, has been named a finalist for the Philadelphia Alliance for Capital and Technologies (PACT) Technology Company of the Year award. ERT is one of only three companies nominated to receive this recognition.

[Read More]

Caligor appoints Andrea Chopek and Craig LaMarca to Clinical Trial Services Business Unit

Monday, February 13, 2017

Caligor Opco, which specializes in global comparator sourcing, early access to medicines and drug life-cycle management, has named two pharmaceutical executives to its Clinical Trial Services (CTS) business unit. Andrea Chopek has been appointed global head of Business Development for CTS. Craig LaMarca has been named global head of Business Development for TrialAssist, a business line under CTS. Both positions are new for the company, which recently expanded its international operations with the opening of a state-of-the-art, 33,000-square-foot facility in the UK.

[Read More]